Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients

Plain-language guide to PMID 27827962 (2016): placebo-controlled randomized controlled trial study of LL-37 (cathelicidin) and Parathyroid Hormone (PTH 1-84), hyperparathyroidism.

Key Facts

PMID: 27827962
Journal: Nutrients
Year: 2016
Study type: Randomized Controlled Trial
Authors: Zheng JQ et al. (9 authors)
DOI: 10.3390/nu8110708

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of LL-37 (cathelicidin) and Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a randomized controlled trial.

Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got LL-37 (cathelicidin) and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the LL-37 (cathelicidin) group a baseline to be compared against.

Serum 25(OH)D₃, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up.

What Was Measured

Topics PubMed links to this paper include Antimicrobial Cationic Peptides, Calcifediol, Cholecalciferol, Drug Interactions, Ergocalciferols, Hyperparathyroidism, Secondary and Kidney Failure, Chronic.

The authors tagged it with the keywords human cathelicidin (hCAP-18), maintenance hemodialysis (HD), paricalcitol, secondary hyperparathyroidism (SHPT) and study.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of LL-37 (cathelicidin) and Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Nutrients), a journal based in Switzerland.

More context: the LL-37 (cathelicidin) compound page and the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.

Our Notes on the Compounds

LL-37 (cathelicidin): The body's own antimicrobial peptide, described as the strongest of its class.

Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.